TMO - Thermo Fisher Scientific Inc.
NEXT EARNINGS:
Apr 29, 2026
EPS Est: $5.27
|
Rev Est: $10.9B
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$643.69
DETAILS
HIGH:
$750.00
LOW:
$561.00
MEDIAN:
$650.00
CONSENSUS:
$643.69
UPSIDE:
24.84%
Market Cap:
193.72B
Volume:
910,898
Avg Volume:
2,189,158
52 Week Range:
385.46-643.99
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Beta:
0.95
Last Dividend:
$1.72
Exchange:
NYSE
Country:
US
Employees:
125,000
IPO Date:
1980-03-17
EPS (TTM):
17.77
P/E Ratio:
32.34
Revenue (TTM):
44.56B
Total Assets:
110.34B
Total Debt:
39.38B
Cash & Equiv:
9.85B
Rev Growth (5Y):
6.7%
EPS Growth (5Y):
2.0%
FCF Growth (5Y):
-1.6%
ROCE:
8.5%
Debt/Equity:
0.74
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-01-29 | $6.57 | $6.45 | +1.9% | $12.2B | $11.9B | +2.2% |
| 2025-10-22 | $5.79 | $5.50 | +5.3% | $11.1B | $10.9B | +1.9% |
| 2025-07-23 | $5.36 | $5.23 | +2.5% | $10.9B | $10.7B | +1.6% |
| 2025-04-23 | $5.15 | $5.10 | +1.0% | $10.4B | $10.2B | +1.3% |
| 2025-01-30 | $6.10 | $5.94 | +2.7% | $11.4B | $11.3B | +1.0% |
| 2024-10-23 | $5.28 | $5.25 | +0.6% | $10.6B | $10.6B | -0.3% |
| 2024-07-24 | $5.37 | $5.12 | +4.9% | $10.5B | $10.5B | +0.3% |
| 2024-04-24 | $5.11 | $4.71 | +8.5% | $10.3B | $10.2B | +1.9% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.56B | 42.88B | 42.86B | 44.91B | 39.21B | 32.22B | 25.54B | 24.36B | 20.92B | 18.27B | 16.97B | 16.89B |
| Net Income | 6.74B | 6.33B | 6.00B | 6.95B | 7.72B | 6.38B | 3.70B | 2.94B | 2.23B | 2.02B | 1.98B | 1.89B |
| EPS | 17.77 | 16.58 | 15.53 | 17.73 | 19.61 | 16.10 | 9.24 | 7.31 | 5.64 | 5.12 | 4.96 | 4.76 |
| Total Assets | 110.34B | 97.32B | 98.73B | 97.15B | 95.12B | 69.05B | 58.38B | 56.23B | 56.67B | 45.91B | 40.83B | 42.85B |
| Total Debt | 39.38B | 32.77B | 36.42B | 36.07B | 36.34B | 22.55B | 18.49B | 18.99B | 21.01B | 16.63B | 12.47B | 14.56B |
| Cash & Equivalents | 9.85B | 4.01B | 8.08B | 8.52B | 4.48B | 10.32B | 2.40B | 2.10B | 1.33B | 786.00M | 452.10M | 1.34B |
| Operating Cash Flow | 7.82B | 8.67B | 8.41B | 9.15B | 9.54B | 8.29B | 4.97B | 4.54B | 4.00B | 3.16B | 2.82B | 2.62B |
| Free Cash Flow | 6.29B | 7.27B | 6.93B | 6.91B | 7.02B | 6.82B | 4.05B | 3.79B | 3.50B | 2.71B | 2.39B | 2.19B |
| FCF per Share | 16.74 | 19.02 | 17.95 | 17.63 | 17.82 | 17.21 | 10.12 | 9.42 | 8.85 | 6.87 | 6.00 | 5.50 |
| Book Value | 53.41B | 49.58B | 46.73B | 43.98B | 40.79B | 34.51B | 29.68B | 27.59B | 25.41B | 21.54B | 21.35B | 20.55B |
| Cash & ST Investments | 10.11B | 5.57B | 8.08B | 8.52B | 4.48B | 10.32B | 2.40B | 2.10B | 1.33B | 786.00M | 452.10M | 1.34B |
| ROC Equity | 0.13 | 0.13 | 0.13 | 0.16 | 0.19 | 0.18 | 0.12 | 0.11 | 0.09 | 0.09 | 0.09 | 0.09 |